Hepion Pharmaceuticals (HEPA) Projected to Post Quarterly Earnings on Tuesday

Hepion Pharmaceuticals (NASDAQ:HEPA) is expected to announce its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($200.00) per share for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 7:00 AM ET.

Hepion Pharmaceuticals Stock Up 3.7%

NASDAQ:HEPA traded up $0.00 during mid-day trading on Tuesday, hitting $0.06. 19,576 shares of the company traded hands, compared to its average volume of 17,488. The stock’s fifty day moving average price is $0.05 and its 200-day moving average price is $0.06. Hepion Pharmaceuticals has a one year low of $0.03 and a one year high of $0.10. The firm has a market cap of $640,360.00, a price-to-earnings ratio of -0.01 and a beta of 1.52.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases. The company harnesses epigenetic and autophagy‐modulating approaches to address high unmet medical needs in conditions such as nonalcoholic steatohepatitis (NASH), fibrosis and hepatocellular carcinoma. Hepion’s research platform is designed to identify and advance small molecules that can halt or reverse liver damage by targeting key pathways involved in inflammation, cellular stress and tissue remodeling.

The company’s lead therapeutic candidate, CRV431, is a cyclophilin inhibitor being evaluated in Phase 2 clinical trials for the treatment of NASH with bridging fibrosis.